Personalized Medicine To Be HHS Focus In Administration’s Final Years
This article was originally published in The Gray Sheet
Executive Summary
Facilitating the development of personalized medicine will be a priority for HHS during the remainder of the Bush Administration, according to HHS Secretary Michael Leavitt
You may also be interested in...
Litigation In Brief
St. Jude angers investors: Multiple class action suits filed against the firm charge that it misled investors about its implantable cardioverter defibrillator sales in the fourth quarter of 2005 to inflate its stock price. Law firm Roy Jacobs & Associates, for one, charges that St. Jude reported false information to "achieve extraordinary personal benefits for top insiders, such as CEO Daniel J. Starks, who sold an unusual number of shares in the open market in the early months of 2006." The lawsuits come after St. Jude reported first quarter earnings April 4 of $784 mil., far below its previously projected sales of $799 mil.-$839 mil. (1"The Gray Sheet" April 10, 2006, p. 7)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.